Anti-Beta-Amyloid Peptide (N-terminus) Antibody

Neurodegenerative Disease, Alzheimer's Disease

United States

100 µg/mL

Antibodies were analyzed by immunohistochemistry (at a concentration of 3 µg/mL) using fluorescein-labeled goat anti-chicken IgY (1:500 dilution, Aves Labs Cat.# F-1005) or HRP-labeled goat anti-chicken IgY (1:2000 dilution, Aves Labs, Cat.# H-1004) as the secondary reagent.

Beta-Amyloid peptide antibodies were generated against a KLH-conjugated N-terminal sequence contained within both the 40- and 42-amino acid versions of the human Beta-Amyloid peptide (i.e., DAE FRH DSG YEV HHQ KL) (Amyloid Precursor Protein residues #672-688).

Beta-Amyloid peptide is a 40- or 42-amino acid fragment of the human Beta-Amyloid Peptide: Precursor Protein (770 amino acids) produced by the proteolytic actions of Beta and Gamma-secretases. Both forms of Beta-Amyloid peptide are rather insoluble and tend to self-aggregate into distinctive extracellular "plaques." These plaques are evident in brains from patients with Alzheimer's disease as well as in brains from individuals with a history of traumatic head injuries. In the case of Alzheimer's disease, it has been suggested that these extracellular Beta-Amyloid peptide plaques are themselves cytotoxic (rather than simply being markers of brain pathology), and are responsible for the dendritic pruning and other neurodegenerative changes seen.

Polyclonal

1:2000-1:5000

Human

12 months from receipt of product

Chickens were immunized with a synthetic peptide (corresponding to DAE FRH DSG YEV HHQ KL, residues #1-17 of the amyloid beta-peptide) coupled to keyhole limpet hemocyanin (KLH). After repeated injections, immune eggs were collected, and the IgY fractions were purified from the yolks. These IgY fractions were then affinity-purified using a peptide column to which the same peptide was attached. Finally, the antibody concentration was adjusted to 100 ug/ml and filter-sterilized.